Reviva Pharmaceuticals (RVPH) KOL Event summary

Introduction and agenda

• The event presented phase III RECOVER trial results for brilaroxazine in schizophrenia, focusing on efficacy, safety, and novel biomarker data, including vocal biomarkers.

• The agenda included trial results, vocal biomarker analysis, and a Q&A session, all within a 60-minute format.

• The R&D pipeline overview highlighted brilaroxazine's development for schizophrenia and potential expansion to other psychiatric and inflammatory conditions.

• The event featured Dr. Mark Opler and Dr. Brian Kirkpatrick, both recognized experts in psychiatric research and schizophrenia.

Market insights and analysis

• Schizophrenia affects over 1% of the global population, with high rates of treatment resistance and discontinuation.

• Current therapies often fail to address all symptom domains, especially negative symptoms and treatment adherence.

• The estimated market opportunity for schizophrenia treatments is $13.4B by 2032.

Investment thesis and rationale

• Brilaroxazine demonstrated robust efficacy across primary and secondary endpoints in phase II and III trials, with rapid onset and broad-spectrum activity.

• The drug showed consistent results in both Phase 2 and Phase 3 trials, with effect sizes comparable or superior to leading antipsychotics.

• The drug showed potential for expansion into other psychiatric and inflammatory indications, supported by translational and biomarker data.

• Regulatory discussions are ongoing, with a planned NDA submission in Q1 2026.